No two cancers are the same. Let’s treat it that way.

At Eigen, we’re tackling tumor heterogeneity by utilizing our platform to design combination therapies.

Targeted therapies are incredibly effective

Antibody-drug conjugates, radioligand therapies, and other targeted therapies eliminate cells that express a specific target associated with cancer.

But only for some cancers

When target levels vary - which is the case for most cancers - cancer cells escape treatment, decreasing eligibility for patients to receive targeted therapies, and increasing risk of relapse in others.

We help targeted therapies hit their mark

Eigen develops co-therapies that mark cancer cells and unmark healthy cells by modulating the expression of their targets. With better control of target levels, we can reduce side effects and improve outcomes for more patients.

We’ve built a platform to scale ‍co-therapy development

Our discovery engine uses machine learning and automation to improve existing targeted therapies, develop combination therapies, and make them available for a wider range of cancers.

Biology

High-throughput, high-speed combinatorial screening determines drug therapeutic window

Complex phenotypic screening workflow creates more realistic in vitro models

Robotics

Automated laboratory reduces the time it takes to identify promising therapies

Robotic workcells dutifully execute millions of repetitive laboratory actions with consistency

Software

Custom-developed lab operations software allows for complex biology experiments to be performed like a well-oiled machine

Sophisticated machine learning models and the world’s largest heterogeneity atlas guide co-therapy discovery

A multidisciplinary problem needs a multidisciplinary team

By combining our expertise in engineering, biology, robotics, and data science, we’re building a platform at Eigen that will enable a single scientist to accomplish feats that would normally take an entire team.

Transon Nguyen

CEO, Co-Founder

Kathryn Vanderlaag, Ph.D.

CSO

Erik Werner, Ph.D.

Lead Engineer

Investors

Make your mark at Eigen

With more effective, less toxic treatments, we can give hope to patients and help more people benefit from targeted therapies. Join our team and solve difficult challenges while saving lives.